Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis

Respiratory Medicine

Volumn 103, Issue 12, 2009, Pages 1777-1790

  Ahmad, Suhail ^a   Mokaddas, Eiman ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Management; MDR TB; Rapid diagnosis; Treatment

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; VIOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CLINICAL TRIAL; CROSS RESISTANCE; DIRECTLY OBSERVED THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; EARLY DIAGNOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; GENE MUTATION; GENE TARGETING; GENOTYPE; HUMAN; INFECTION CONTROL; INFECTION RISK; LUNG TUBERCULOSIS; MOLECULAR EVOLUTION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; PHENOTYPE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPUTUM ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 70350707756     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.07.010     Document Type: Review

References (132)

1. World Health Organization. Global tuberculosis control: surveillance, planning and financing. WHO report 2008. WHO/HTM/TB/2008.393 (2008), WHO, Geneva, Switzerland
2. Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., and Dye C. Tuberculosis. Lancet 362 (2003) 887-899
3. Wells C.D., Cegielski J.P., Nelson L.J., et al. HIV infection and multidrug-resistant tuberculosis-the perfect storm. J Infect Dis 196 Suppl. 1 (2007) S86-107
4. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council Investigation. Br Med J 4582 (1948) 769-782
5. Mitchison D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66 (1985) 219-225
6. Mitchison D.A. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 171 (2005) 699-706
7. American Thoracic Society, CDC, and Infectious Disease Society of America. Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep 52 (2003) 1-77
8. Palaci M., Dietze R., Hadad D.J., et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol 45 (2007) 4064-4066
9. World Health Organization. Anti-tuberculosis drug resistance in the world: fourth Global report. WHO/HTM/TB/2008.394 (2008), WHO, Geneva, Switzerland
10. Drobniewski F., Balabanova Y., and Ruddy M. Rifampin- and multidrug-resistant tuberculosis in Russian civilians and prison inmates: dominance of the Beijing strain family. Emerg Infect Dis 8 (2002) 1320-1326
11. Kimerling M.E., Phillips P., Patterson P., Hall M., Robinson C.A., and Dunlap N.E. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 113 (1998) 1178-1183
12. Mokaddas E., Ahmad S., Abal A.T., and Al-Shami A.S. Molecular fingerprinting reveals familial transmission of rifampin-resistant tuberculosis in Kuwait. Ann Saudi Med 25 (2005) 150-153
13. Aziz M.A., Wright A., Laszlo A., et al. for the WHO/International Union Against Tuberculosis and Lung Disease global project on anti-tuberculosis drug resistance surveillance. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 368 (2006) 2142-2154
14. Zignol M., Hosseini M.S., Wright A., et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194 (2006) 479-485
15. Mitnick C.D., Castro K.G., Harrington M., Sacks L.V., and Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 4 (2007) e292
16. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 55 (2006) 301-305
17. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 7 (2009) 81-87
18. Gandhi N.R., Moll A., Sturn A.W., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368 (2006) 1554-1556
19. Zhang Y., Heym B., Allen B., Young D., and Cole S.T. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358 (1992) 591-593
20. Telenti A., Imboden P., Marchesi F., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341 (1993) 647-650
21. Vilcheze C., Wang F., Arai M., et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 12 (2006) 1027-1029
22. Ramaswamy S., and Musser J.M. Molecular genetics basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 79 (1998) 3-29
23. Johnson R., Streicher E., Louw G., Warren R.M., van Helden P.D., and Victor T.C. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 8 (2006) 97-111
24. Ramaswamy S., Reich R., Dou S., et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 47 (2003) 1241-1250
25. Abal A.T., Ahmad S., and Mokaddas E. Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. Microb Drug Resist 8 (2002) 99-105
26. Mokrousov I., Narvskaya O., Otten T., Limeschencko E., Steklova L., and Vyshnevskiy B. High prevalence of Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates of from Northwestern Russia, 1996-2001. Antimicrob Agents Chemother 46 (2002) 1417-1424
27. Silva M.S.N., Senna S.G., Ribeiro M.O., et al. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol 41 (2003) 4471-4474
28. Hazbon M.H., Brimacombe M., del Valle M.B., et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 50 (2006) 2640-2649
29. Mokaddas E., Ahmad S., and Samir I. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005. Int J Tuberc Lung Dis 12 (2008) 319-325
30. Van Rie A., Warren R., Mshanga I., et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol 39 (2001) 636-641
31. Siddiqi N., Shamim M., Hussain S., et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob Agents Chemother 46 (2002) 443-450
32. Afanas'ev M.V., Ikryannikova L.N., Il'ina E.N., et al. Molecular characteristics of rifampicin- and isoniazid resistant Mycobacterium tuberculosis isolates from Russian Federation. J Antimicrob Chemother 59 (2007) 1057-1064
33. Ahmad S., Mokaddas E., and Fares E. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn Microbiol Infect Dis 44 (2002) 245-252
34. Sheng J., Li J., Sheng G., et al. Characterization of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis from eastern China. J Appl Microbiol 105 (2008) 904-911
35. Heep M., Brandstatter B., Rieger U., et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 39 (2001) 107-110
36. Ahmad S., and Mokaddas E. The occurrence of rare rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from Kuwait. Int J Antimicrob Agents 26 (2005) 205-212
37. Yang B., Koga H., Ohno H., et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 42 (1998) 621-628
38. Cavusoglu C., Karaca-Derici Y., and Bilgic A. In-vitro activity of rifabutin against rifampicin-esistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 10 (2004) 662-665
39. Scorpio A., and Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2 (1996) 662-667
40. Sekiguchi J.I., Nakamura T., Miyoshi-Akiyama T., et al. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains. J Clin Microbiol 45 (2007) 2802-2807
41. Ramaswamy S., Amin A.G., Koksel S., et al. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44 (2000) 326-336
42. Telenti A., Phillipp W., Sreevatsan S., et al. The emb operon, a unique gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 3 (1997) 567-570
43. Safi H., Sayers B., Hazbon M.H., and Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid and rifampin. Antimicrob Agents Chemother 52 (2008) 2027-2034
44. Starks A.M., Gumusboga A., Plikaytis B.B., Shinnick T.M., and Posey J.E. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 53 (2009) 1061-1066
45. Ahmad S., Jaber A.A., and Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis 87 (2007) 123-129
46. Sreevatsan S., Pan X., Stockbauer K.E., Williams D.L., Kreisworth B.N., and Musser J.M. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic locations. Antimicrob Agents Chemother 40 (1996) 1024-1026
47. Cooksey R.C., Morlock G.P., McQueen A., Glickman S.E., and Crawford J.T. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City. Antimicrob Agents Chemother 40 (1996) 1186-1188
48. Maus C.E., Pilkaytis B.B., and Shinnick T.M. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49 (2005) 3192-3197
49. Maus C.E., Pilkaytis B.B., and Shinnick T.M. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49 (2005) 571-577
50. Rustomjee R., Lienhardt C., Kanyok T., et al. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12 (2008) 128-138
51. Ginsburg A.S., Grosset J.H., and Bishai W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 3 (2003) 432-442
52. Pitaksajjakul P., Wongwit W., Punprasit W., Eampokalap B., Peacock S., and Ramasoota P. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health 36 (2005) 228-237
53. Wang J.Y., Lee L.N., Lai H.C., et al. Fluoroquinolones resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 59 (2007) 860-865
54. Morlock G.P., Metchock B., Sikes D., Crawford J.T., and Cooksey R.C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 47 (2003) 3799-3805
55. Brodie D., and Schluger N.W. The diagnosis of tuberculosis. Clin Chest Med 26 (2005) 247-271
56. Palomino J.C. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J 26 (2005) 339-350
57. Cheng V.C.C., Yew W.W., and Yuen K.Y. Molecular diagnostics in tuberculosis. Eur J Clin Microbiol Infect Dis 24 (2005) 711-720
58. Mokaddas E., and Ahmad S. Development and evaluation of a multiplex PCR for rapid detection and differentiation of Mycobacterium tuberculosis complex members from non-tuberculous mycobacteria. Jap J Infect Dis 60 (2007) 140-144
59. Tortoli E., Mariottini A., and Mazarelli G. Evaluation of INNO-LiPA MYCOBACTERIA v2: improved reverse hybridization multiple DNA probe assay for mycobacterial identification. J Clin Microbiol 41 (2003) 4418-4420
60. Russo C., Tortoli E., and Manichella D. Evaluation of the new Genotype Mycobacterium assay for identification of mycobacterial species. J Clin Microbiol 44 (2006) 334-339
61. Mokaddas E., and Ahmad S. Species spectrum of nontuberculous mycobacteria causing infections in Kuwait. Curr Microbiol 56 (2008) 413-417
62. Tortoli E., Benedetti M., Fontanelli A., and Simonetti T. Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion. J Clin Microbiol 40 (2002) 607-610
63. Scarparo C., Ricordi P., Ruggiaro G., and Piccoli P. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J Clin Microbiol 42 (2004) 1109-1114
64. Piersimoni C., Olivieri A., Benacchio L., and Scarparo C. Current perspective on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol 44 (2006) 20-28
65. Rusch-Gerdes S., Pfyffer G.E., Casal M., Chadwick M., and Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line and newer antimicrobials. J Clin Microbiol 44 (2006) 688-692
66. Moore D.A.J., Evans C.A.W., Gilman R.H., et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 355 (2006) 1539-1550
67. Shiferaw G., Woldeamanuel Y., Gebeyehu M., Girmachew F., Demessie D., and Lemma E. Evaluation of microscopic observation drug susceptibility assay for the detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 45 (2007) 1093-1097
68. Ejigu G.S., Woldeamanuel Y., Shah N.S., Gebeyehu M., Silassie A., and Lemma E. Microscopic-observation drug susceptibility assay provides rapid and reliable identification of MDR-TB. Int J Tuberc Lung Dis 12 (2008) 332-337
69. Palomino J.C., Martin A., and Portaels F. Rapid drug resistance detection in Mycobacterium tuberculosis. a review of colourimetric methods. Clin Microbiol Infect 13 (2007) 754-762
70. Abate G., Aseffa A., Selassie A., et al. Direct colorimetric assay for rapid detection of rifampin-resistant Mycobacterium tuberculosis. J Clin Microbiol 42 (2004) 871-873
71. Martin A., Portaels F., and Palomino J.C. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 59 (2007) 175-183
72. Affolabi D., Odoun M., Martin A., Palomino J.C., Anagonou S., and Portaels F. Evaluation of direct detection of Mycobacterium tuberculosis rifampin resistance by a nitrate reductase assay applied to sputum samples in Cotonou, Benin. J Clin Microbiol 45 (2007) 2123-2125
73. Hazbon M.H., Guarin N., Ferro B.E., et al. Photographic and luminometric detection of luciferase reporter phages for susceptibility testing of Mycobacterium tuberculosis isolates. J Clin Microbiol 41 (2003) 4865-4869
74. Banaiee N., January V., Barthus C., et al. Evaluation of semiautomated reporter phage assay for susceptibility testing of Mycobacterium tuberculosis isolates in South Africa. Tuberculosis 88 (2008) 64-68
75. Traore H., van Deun A., Shamputa I.C., Rigouts L., and Portaels F. Direct detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay. J Clin Microbiol 44 (2006) 4384-4388
76. Hillemann D., Gerdes R.S., and Richter E. Evaluation of Genotype MTBDR plus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45 (2007) 2635-2640
77. Feasibility of the GenoType MTBDR sl assay for fluoroquinolone, amikacin-capreomycin and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 47 (2009) 1767-1772
78. Mokrousov I., Bhanu N.V., Suffys P.N., Kadival G.V., Yap S.F., Cho S.N., et al. Multicenter evaluation of reverse line blot assay for detection of drug resistance in Mycobacterium tuberculosis clinical isolates. J Microbiol Methods 57 (2004) 323-335
79. Sougakoff W., Rodrigues M., Truffot-Pernot C., et al. Use of a high-density DNA probe array for detecting mutations involved in rifampicin resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 10 (2004) 289-294
80. Bergval I.L., Vijzelaar R.N.C.P., Dalla Costa E.R., et al. Development of multiplex assay for rapid characterization of Mycobacterium tuberculosis. J Clin Microbiol 46 (2008) 689-699
81. Cockerill III F.R., Uhl J.R., Temesgen Z., et al. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis 171 (1995) 240-245
82. Ahmad S., Mokaddas E., and Jaber A.A. Rapid detection of ethambutol-resistant Mycobacterium tuberculosis strains by PCR-RFLP targeting embB codons 306 and 497 and iniA codon 501 mutations. Mol Cell Probes 18 (2004) 299-306
83. Ahmad S., and Mokaddas E. Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East. Int J Antimicrob Agents 23 (2004) 473-479
84. Marttila H.J., Makinen J., Marjamaki M., and Soini H. Prospective evaluation of pyrosequencing for the rapid detection of isoniazid and rifampin resistance in clinical Mycobacterium tuberculosis isolates. Eur J Clin Microbiol Infect Dis 28 (2009) 33-38
85. Ruiz M Torres M.J., Llanos A.C., Arroyo A., Palomares J.C., and Aznar J. Direct detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis in auramine-rhodamine-positive sputum specimens by real-time PCR. J Clin Microbiol 42 (2004) 1585-1589
86. Espasa M., Gonzales-Martin J., Alcaide F., et al. Direct detection in clinical samples of multiple gene mutations causing resistance of Mycobacterium tuberculosis to isoniazid and rifampicin using fluorogenic probes. J Antimicrob Chemother 55 (2005) 860-865
87. Viveiros M., Leandro C., Rodrigues L., et al. Direct application of the INNO-LiPA Rif. TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. J Clin Microbiol 43 (2005) 4880-4884
88. Vijdea R., Stegger M., Sosnovskaja A., Andersen A.B., Thomsen V.O., and Bang D. Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis 27 (2008) 1079-1086
89. Evans J., Stead M.C., Nicol M.P., and Segal H. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. J Antimicrob Chemother 63 (2009) 11-16
90. Giannoni F., Iona E., Sementilli F., Brunori L., Pardini M., Migliori G.B., et al. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. J Clin Microbiol 49 (2005) 2928-2933
91. Kim S.Y., Park Y.J., Song E., et al. Evaluation of the CombiChip Mycobacteria Drug-Resistance detection DNA chip for identifying mutations associated with resistance to isoniazid and rifampin in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 54 (2006) 203-210
92. Donald P.R., and Diacon A.H. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis 88 (2008) S75-S83
93. Fortun J., Martin-Davila P., Navas E., et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 56 (2005) 180-185
94. Dietze R., Hadad D.J., McGee B., et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 178 (2008) 1180-1185
95. Espinal M.A., Kim S.J., Suarez P.G., et al. Standard short-course chemotherapy for drug-resistant tuberculosis. JAMA 283 (2000) 2537-2545
96. Mak A., Thomas A., Sel Granado M., Zalekis R., Mouzafarova N., and Menzies D. Influence of multidrug-resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 178 (2008) 306-312
97. Lew W., Pai M., Oxdale O., Martin D., and Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 149 (2008) 123-134
98. Fischl M.A., Daikos G.L., Uttamchandani R.B., et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med 117 (1992) 184-190
99. Park M.M., Davis A.L., Schluger N.W., Cohen H., and Rom W.N. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 153 (1996) 317-324
100. Turett G.S., Telzak E.E., Torian L.V., et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 21 (1995) 1238-1244
101. Mukherjee J.S., Rich M.L., Socci A.R., et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363 (2004) 474-481
102. Furin J. The clinical management of drug-resistant tuberculosis. Curr Opin Pulm Med 13 (2007) 212-217
103. Mitnick C.D., Appleton S.C., and Shin S.S. Epidemiology and treatment of multidrug-resistant tuberculosis. Semin Respir Crit Care Med 29 (2008) 499-524
104. Harries A.D., Boxshall M., Phiri S., and Kwanjana J. Providing HIV care for tuberculosis patients in sub-Saharan Africa. Int J Tuberc Lung Dis 10 (2006) 1306-1311
105. Rich M.L., Socci A.R., Mitnick C.D., et al. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis 10 (2006) 290-296
106. Perkins M.D., and Smith L.M. Facing the crises: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 196 Suppl. 1 (2007) S15-S27
107. Leimane V., Riekstina V., Holtz T.H., et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365 (2005) 318-326
108. Saravia J.C., Appleton S.C., Rich M.L., Sarria M., Bayona J., and Becerra M.C. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 9 (2005) 421-429
109. Shin S.S., Yagui M., Ascencios L., et al. Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerg Infect Dis 15 (2008) 701-708
110. Holtz T.H., Sternberg M., Kammerer S., et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 144 (2006) 650-659
111. Han L.L., Sloutsky A., Canales R., et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric treatment with standardized regimens. Int J Tuberc Lung Dis 9 (2005) 818-821
112. Dominguez-Castellano A., Muniain M.A., Muniain M.A., et al. Factors associated with time to sputum smear conversion in active pulmonary tuberculosis. Int J Tuberc Lung Dis 7 (2003) 432-438
113. Shin S.S., Pasechnikov A.D., Gelmanova I.Y., et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 10 (2006) 402-408
114. Riekstina V., Leimane V., Holtz T.H., Leimans J., and Wells C.D. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. Int J Tuberc Lung Dis 11 (2007) 585-587
115. Van Deun A., Salim M.A., Das A.P., Bastian I., and Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 8 (2004) 560-567
116. Nathanson E., Lambregts-van Weezenbeek C., Rich M.L., et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 12 (2006) 1389-1397
117. Tupasi T.E., Gupta R., Quelapio M.I., et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 3 (2006) e352
118. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis (2006), WHO, Geneva, Switzerland
119. Mitchison D.A. Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Semin Respir Crit Care Med 25 (2004) 307-315
120. Connolly L.E., Edelstein P.H., and Ramakrishnan L. Why is long-term therapy required to cure tuberculosis. PLoS Med 4 (2007) e120
121. Salomon J.A., Lloyd-Smith J.O., Getz W.M., et al. Prospects for advancing tuberculosis control through novel therapies. PLoS Med 3 (2006) e273
122. Ginsberg A.M. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 29 (2008) 552-559
123. Stover C.K., Warrener P., VanDevanter D.R., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405 (2000) 962-966
124. Nueremberger E., Tyagi S., Tasneen T., et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52 (2008) 1522-1524
125. Matsumoto M., Hashizume H., Tomishige T., et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3 (2006) e466
126. Manjunatha U.H., Boshoff H., Dowd C.S., et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 103 (2006) 431-436
127. Andries K., Verhasselt P., Guillemont J., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307 (2005) 223-227
128. Lounis N., Veziris N., Chauffour A., Truffot-Pernot C., Andries K., and Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 50 (2006) 3543-3547
129. Protopopova M., Hanrahan C., Nikonenko B., et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56 (2005) 968-974
130. Nikonenko B.V., Protopopova M.N., Samala R., Einck L., and Nacy C.A. Drug therapy of experimental TB: improved outcome by combining SQ109, a new diamine antibiotic with existing TB drugs. Antimicrob Agents Chemother 51 (2007) 1563-1565
131. Villar R., Vicente E., Solano B., et al. In vitro and in vivo antimycobacterial acitivities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J Antimicrob Chemother 62 (2008) 547-554
132. Lilienkampf A., Mao J., Wan B., Wang Y., Franzblau S.G., and Kozikowski A.P. Structure-activity relationships for a series of quinoline-based compounds against replicating and nonreplicating. J Med Chem 52 (2009) 2109-2118